As a representative of the sclerosant class of cleaning agents, polidocanol has demonstrated exceptional clinical efficacy and safety through numerous clinical studies, standing out as an excellent choice for the sclerotherapy of varicose veins.

Efficacy: Compared to traditional surgery, polidocanol sclerotherapy significantly improves surgical parameters (shorter operation time, reduced intraoperative bleeding, decreased hospital stay) and lowers the rate of postoperative recurrence. The combination of polidocanol sclerotherapy and surgery significantly improves symptoms of lower extremity varicose veins and reduces the Venous Clinical Severity Score (VCSS).

Safety: The use of polidocanol sclerosant injections in the hospital and outpatient settings for the treatment of lower extremity varicose veins is safe, with no reports of serious complications such as deep vein thrombosis.